In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents

Chapter 2 BCL2 Inhibitors: insights into resistance
Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib
Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms
Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents
Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.